Frontiers in endocrinology · 2026
Material-driven glucose responsiveness in insulin delivery systems: carrier selection and performance.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Zhihan, Jiang Jingge, Zhu Ziyu, Luo Cheng, Xu Chunyi, Chen Chuanpin, Ren Guoqin, Huang Ruofei, He Dongjuan
Аннотация
Conventional subcutaneous insulin therapy faces limitations in patient adherence and carries a persistent risk of hypoglycemia, primarily due to the challenges of achieving precise dosing. To address this, glucose-responsive insulin delivery systems have been developed to autonomously adjust insulin release in direct response to real-time fluctuations in blood glucose levels. This approach offers a promising pathway toward achieving more physiological glycemic control. This review systematically summarizes recent advances in the design of such intelligent systems, with a focus on two fundamentally interconnected components: the ongoing evolution of glucose-sensing mechanisms, which encompass enzymatic, non-enzymatic, and transporter-mediated strategies, and the parallel development of advanced carrier materials, including metal-organic frameworks, smart polymers, and bio-derived materials. In addition to outlining these technological developments, this work provides a balanced analysis of the operational principles, relative merits, and key translational challenges inherent in current system designs, with particular attention to long-term biocompatibility, stability, and safety. By presenting a coherent synthesis of the field's current landscape and its potential future directions, this review aims to inform and support the rational development of next-generation glucose-responsive insulin therapies with stronger prospects for clinical translation.